

# Global mRNA Vaccines and Therapeutics Market - 2025-2033

<https://marketpublishers.com/r/G421DCD4B839EN.html>

Date: May 2025

Pages: 168

Price: US\$ 4,350.00 (Single User License)

ID: G421DCD4B839EN

## Abstracts

### Global mRNA Vaccines and Therapeutics Market Size - Industry Trends & Outlook

The global mRNA Vaccines and Therapeutics market size reached US\$ 410 Million in 2024 and is expected to reach US\$ 850.90 Million by 2033, growing at a CAGR of 8.5% during the forecast period 2025-2033.

The mRNA vaccines and therapeutics market is experiencing rapid growth, driven by the proven success of mRNA-based COVID-19 vaccines and the expanding potential of this technology across a range of therapeutic areas. Unlike traditional vaccines, mRNA vaccines work by instructing cells to produce proteins that mimic disease-causing agents, triggering targeted immune responses with greater precision and fewer side effects.

Key market drivers include accelerated R&D investment, technological advancements in delivery systems, and strong regulatory momentum following the pandemic.

Opportunities lie in expanding into new indications such as influenza, RSV, HIV, and personalized oncology treatments.

### Global mRNA Vaccines and Therapeutics Market Dynamics: Drivers & Restraints

#### Growing Cases of Chronic Diseases are Expected to Drive the mRNA Vaccines and Therapeutics Market

The rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and other autoimmune diseases is expected to drive the mRNA vaccines and therapeutics market growth. There is a growing demand for vaccines and therapeutics with the

growing awareness of the increasing incidence of cancer cases. For instance, according to the National Cancer Institute in 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million.

As chronic diseases continue to place a significant strain on global healthcare systems, the demand for more effective treatments and preventative solutions is steadily increasing. mRNA technology, which has already proven its effectiveness in COVID-19 vaccines, holds great promise for developing targeted therapies for conditions like cancer and other chronic illnesses.

By utilizing mRNA's ability to direct cells to produce specific proteins, researchers have the potential to create vaccines and therapeutics that address the root causes of diseases, offering more targeted treatments with fewer side effects. This growing need for advanced, personalized approaches to managing chronic diseases is driving the expansion of the mRNA-based therapeutics market, positioning it as one of the fastest-growing areas in modern medicine.

#### Competition from Alternative Vaccines and Therapeutics is Expected to Hinder the mRNA Vaccines and Therapeutics Market

Competition from alternative technologies could hinder the growth of the mRNA vaccines and therapeutics market by offering potentially safer or more established solutions. For instance, protein subunit vaccines, viral vector-based vaccines, and monoclonal antibodies are alternative platforms that have been used successfully in various treatments and may be preferred by some healthcare providers or patients due to their familiarity.

These alternatives may also present fewer concerns related to safety, storage requirements, or production challenges, making them more appealing in certain situations. As a result, the market share for mRNA-based products could face limitations, especially if these competing technologies prove more efficient, cost-effective, or widely accepted in the long run.

#### Global mRNA Vaccines and Therapeutics Market Segment Analysis

The global mRNA vaccines and therapeutics market is segmented based on product type, application, end-user, and region.

## Component Type:

The prophylactic vaccines are expected to hold 48.6% of the global mRNA vaccines and therapeutics market

The prophylactic vaccines segment is poised to dominate the mRNA vaccines and therapeutics market, fueled by the proven success of mRNA technology in addressing infectious diseases, particularly with COVID-19 vaccines. The inherent speed and flexibility of mRNA platforms enable rapid development and scalable production, making them invaluable in responding to emerging health threats and pandemics. This capability has fostered strong confidence in mRNA vaccines, known for delivering robust, long-lasting immunity and their adaptability to new pathogens.

Beyond COVID-19, the development of mRNA vaccines for infectious diseases like influenza and HIV further positions this technology as a key solution for global health challenges. For instance, in June 2024, Moderna's RSV vaccine, mRESVIA, received approval from the U.S. Food and Drug Administration (FDA) for use in adults aged 60 and over, marking the first FDA-approved mRNA vaccine for a disease other than COVID-19. This milestone represents a major advancement in vaccine technology and is expected to broaden the application of mRNA platforms across a wider range of diseases in the future.

As the approval and widespread adoption of mRNA-based vaccines continue to expand, the prophylactic vaccines segment is set to maintain a dominant position in the market, driven by the technology's effectiveness and its potential to address a wide range of infectious diseases.

## Global MRNA Vaccines and Therapeutics Market Geographical Analysis

North America is expected to hold 38.2% of the global mRNA vaccines and therapeutics market

North America is expected to hold a significant position in the global mRNA vaccines and therapeutics market due to several key factors. Several pharmaceutical companies and biotech firms have been at the forefront of mRNA vaccine development, especially in response to the COVID-19 pandemic. These companies' expertise, along with substantial investment in mRNA technology, has positioned North America as a global leader in both research and commercialization of mRNA-based therapies.

For instance, in May 2024, Moderna Inc. received FDA approval for the mRNA RSV vaccine, which will be marketed as mRESVIA. The novel mRNA RSV vaccine is indicated to protect adults aged 60 years and older from lower respiratory tract disease (LRTD) caused by RSV infection. The approval was granted under a breakthrough therapy designation, marking Moderna's second FDA-approved mRNA vaccine.

Additionally, North America benefits from a robust regulatory framework, with agencies such as the U.S. FDA and Health Canada offering significant support in the approval and distribution of mRNA vaccines and therapeutics. This conducive regulatory environment accelerates the approval process, ensuring faster market access and allowing companies to introduce innovative treatments with greater efficiency.

Moreover, the region has robust funding and clinical organizations involved in the development of several vaccines and therapeutics. Several clinical trials are being conducted in the region by companies and organizations, which increases the product portfolio and meets the rising demand for vaccines. For instance, in January 2025, ME Therapeutics Holdings Inc. announced that its first mRNA therapeutic candidate, developed in collaboration with NanoVation Therapeutics, has shown promising anti-cancer activity in a colorectal cancer mouse model. The company plans to follow up studies to validate the results and explore the candidate's mechanism of action.

Additionally, in February 2023, Pfizer Inc. and BioNTech SE initiated a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies' mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicella-zoster virus (VZV). Shingles affects millions of people around the world each year.

In December 2022, Moderna, Inc. and Merck announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.

Asia-Pacific is expected to hold 28.4% of the global mRNA Vaccines and Therapeutics market

The Asia-Pacific region is emerging as the fastest-growing market for mRNA vaccines and therapeutics, driven by robust R&D investment, supportive regulatory frameworks, and increasing public health initiatives.

Japan, in particular, is playing a pivotal role in this growth. For instance, in September 2024, Japan approved ARCT-154 (Kostaive), a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics, designed to protect against the JN.1 Omicron subvariant in adults aged 18 and older. This approval reflects the region's growing commitment to next-generation vaccine technologies and underscores Asia-Pacific's strategic position in advancing mRNA-based solutions for infectious diseases and beyond.

### Global mRNA Vaccines and Therapeutics Market Competitive Landscape

The top companies in the mRNA Vaccines and Therapeutics market include Azra AI, CureMetrix, Inc., ConcertAI, Immunai, MVision AI Inc., Paige AI, Inc., Mindpeak GmbH, Imagen AI Ltd., Predictive Oncology, and Tempus, among others.

### Global mRNA Vaccines and Therapeutics Market Key Developments

In January 2025, Esphera SynBio, a pre-clinical stage synthetic biology company, initiated a new project focused on improving the effectiveness of mRNA vaccines. Utilizing its proprietary technology, the company aims to engineer mRNA vaccines that direct patient cells to produce modified nanomedicines upon delivery, enhancing therapeutic impact and precision.

The global mRNA Vaccines and Therapeutics market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

### Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.

Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.

Supply Chain: Distribution and Supply Chain Managers.

Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.

Academic & Research: Academic Institutions.

## Contents

### 1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

### 2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Product Type
- 2.4. Snippet by Application
- 2.5. Snippet by End-user
- 2.6. Snippet by Region

### 3. DYNAMICS

- 3.1. Impacting Factors
  - 3.1.1. Drivers
    - 3.1.1.1. Growing Cases of Chronic Diseases
    - 3.1.1.2. Increasing Cancer Incidence
  - 3.1.2. Restraints
    - 3.1.2.1. Complications Associated with mRNA Vaccines and Therapeutics
    - 3.1.2.2. Data Privacy and Security Concerns
    - 3.1.2.3. XX
  - 3.1.3. Opportunity
    - 3.1.3.1. Rising Funding from the Government
    - 3.1.3.2. XX
  - 3.1.4. Impact Analysis

### 4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
  - 4.1.1. Emerging Pioneers and Prominent Players
  - 4.1.2. Established Leaders with Largest Marketing Brand
  - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs



#### 4.3. Regulatory and Reimbursement Landscape

4.3.1. North America

4.3.2. Europe

4.3.3. Asia Pacific

4.3.4. Latin America

4.3.5. Middle East & Africa

#### 4.4. Porter's Five Forces Analysis

#### 4.5. Supply Chain Analysis

#### 4.6. Patent Analysis

#### 4.7. SWOT Analysis

#### 4.8. Pipeline Analysis

#### 4.9. Epidemiology Analysis

#### 4.10. Unmet Needs and Gaps

#### 4.11. Recommended Strategies for Market Entry and Expansion

#### 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts

#### 4.13. Pricing Analysis and Price Dynamics

#### 4.14. Key Opinion Leaders

### 5. MRNA VACCINES AND THERAPEUTICS MARKET PRODUCT TYPE OUTLOOK

#### 5.1. Introduction

5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

5.1.2. Market Attractiveness Index, By Product Type

#### 5.2. Prophylactic Vaccines\*

5.2.1. Introduction

5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

#### 5.3. Therapeutic Vaccines

#### 5.4. Therapeutic Drugs

### 6. MRNA VACCINES AND THERAPEUTICS MARKET APPLICATION OUTLOOK

#### 6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

6.1.2. Market Attractiveness Index, By Application

#### 6.2. Cancer\*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

#### 6.3. Infectious Diseases

#### 6.4. Rare Genetic Diseases



## 6.5. Others

# 7. MRNA VACCINES AND THERAPEUTICS MARKET END-USER OUTLOOK

## 7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

7.1.2. Market Attractiveness Index, By End-user

## 7.2. Hospitals & Clinics\*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

## 7.3. Research Organization

## 7.4. Academic Institutes

## 7.5. Others

# 8. MRNA VACCINES AND THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

## 8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

8.1.2. Market Attractiveness Index, By Region

## 8.2. North America

8.2.1. Introduction

8.2.2. Key Region-Specific Dynamics

8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.2.6.1. U.S.

8.2.6.2. Canada

8.2.6.3. Mexico

## 8.3. Europe

8.3.1. Introduction

8.3.2. Key Region-Specific Dynamics

8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.3.6.1. Germany

8.3.6.2. UK

8.3.6.3. France

8.3.6.4. Spain

8.3.6.5. Italy

8.3.6.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. Introduction

8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.4.6.1. China

8.4.6.2. India

8.4.6.3. Japan

8.4.6.4. South Korea

8.4.6.5. Rest of Asia-Pacific

8.5. South America

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.5.6.1. Brazil

8.5.6.2. Argentina

8.5.6.3. Rest of South America

8.6. Middle East and Africa

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

## **9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING**

9.1. Competitive Overview and Key Market Players

9.2. Market Share Analysis and Positioning Matrix

9.3. Strategic Partnerships, Mergers & Acquisitions

9.4. Key Developments in Product Portfolios and Innovations

## 9.5. Company Benchmarking

## 10. COMPANY PROFILES

### Key Players

#### 10.1. AstraZeneca\*

##### 10.1.1. Company Overview

##### 10.1.2. Product Portfolio

###### 10.1.2.1. Product Description

###### 10.1.2.2. Product Key Performance Indicators (KPIs)

###### 10.1.2.3. Historic and Forecasted Product Sales

###### 10.1.2.4. Product Sales Volume

##### 10.1.3. Financial Overview

###### 10.1.3.1. Company Revenue

###### 10.1.3.2. Geographical Revenue Shares

###### 10.1.3.3. Revenue Forecasts

##### 10.1.4. Key Developments

###### 10.1.4.1. Mergers & Acquisitions

###### 10.1.4.2. Key Product Development Activities

###### 10.1.4.3. Regulatory Approvals, etc.

##### 10.1.5. SWOT Analysis

#### 10.2. Pfizer Inc.

#### 10.3. Moderna, Inc.

#### 10.4. BioNTech SE.

#### 10.5. Arcturus Therapeutics, Inc.

#### 10.6. CureVac SE

#### 10.7. Sanofi

#### 10.8. etherna

LIST NOT EXHAUSTIVE

## 11. ASSUMPTION AND RESEARCH METHODOLOGY

### 11.1. Data Collection Methods

### 11.2. Data Triangulation

### 11.3. Forecasting Techniques

### 11.4. Data Verification and Validation

## 12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

## List Of Tables

### LIST OF TABLES

Table 1 Global mRNA Vaccines and Therapeutics Market Value, By Product Type, 2025, 2029 & 2033 (US\$ Million)

Table 2 Global mRNA Vaccines and Therapeutics Market Value, By Application, 2025, 2029 & 2033 (US\$ Million)

Table 3 Global mRNA Vaccines and Therapeutics Market Value, By End-user, 2025, 2029 & 2033 (US\$ Million)

Table 4 Global mRNA Vaccines and Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 5 Global mRNA Vaccines and Therapeutics Market Value, By Product Type, 2025, 2029 & 2033 (US\$ Million)

Table 6 Global mRNA Vaccines and Therapeutics Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 7 Global mRNA Vaccines and Therapeutics Market Value, By Application, 2025, 2029 & 2033 (US\$ Million)

Table 8 Global mRNA Vaccines and Therapeutics Market Value, By Application, 2022-2033 (US\$ Million)

Table 9 Global mRNA Vaccines and Therapeutics Market Value, By End-user, 2025, 2029 & 2033 (US\$ Million)

Table 10 Global mRNA Vaccines and Therapeutics Market Value, By End-user, 2022-2033 (US\$ Million)

Table 11 Global mRNA Vaccines and Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 12 Global mRNA Vaccines and Therapeutics Market Value, By Region, 2022-2033 (US\$ Million)

Table 13 North America mRNA Vaccines and Therapeutics Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 14 North America mRNA Vaccines and Therapeutics Market Value, By Application, 2022-2033 (US\$ Million)

Table 15 North America mRNA Vaccines and Therapeutics Market Value, By End-user, 2022-2033 (US\$ Million)

Table 16 North America mRNA Vaccines and Therapeutics Market Value, By Country, 2022-2033 (US\$ Million)

Table 17 South America mRNA Vaccines and Therapeutics Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 18 South America mRNA Vaccines and Therapeutics Market Value, By

Application, 2022-2033 (US\$ Million)

Table 19 South America mRNA Vaccines and Therapeutics Market Value, By End-user, 2022-2033 (US\$ Million)

Table 20 South America mRNA Vaccines and Therapeutics Market Value, By Country, 2022-2033 (US\$ Million)

Table 21 Europe mRNA Vaccines and Therapeutics Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 22 Europe mRNA Vaccines and Therapeutics Market Value, By Application, 2022-2033 (US\$ Million)

Table 23 Europe mRNA Vaccines and Therapeutics Market Value, By End-user, 2022-2033 (US\$ Million)

Table 24 Europe mRNA Vaccines and Therapeutics Market Value, By Country, 2022-2033 (US\$ Million)

Table 25 Asia-Pacific mRNA Vaccines and Therapeutics Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 26 Asia-Pacific mRNA Vaccines and Therapeutics Market Value, By Application, 2022-2033 (US\$ Million)

Table 27 Asia-Pacific mRNA Vaccines and Therapeutics Market Value, By End-user, 2022-2033 (US\$ Million)

Table 28 Asia-Pacific mRNA Vaccines and Therapeutics Market Value, By Country, 2022-2033 (US\$ Million)

Table 29 Middle East and Africa mRNA Vaccines and Therapeutics Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 30 Middle East and Africa mRNA Vaccines and Therapeutics Market Value, By Application, 2022-2033 (US\$ Million)

Table 31 Middle East and Africa mRNA Vaccines and Therapeutics Market Value, By End-user, 2022-2033 (US\$ Million)

Table 32 Middle East and Africa mRNA Vaccines and Therapeutics Market Value, By Country, 2022-2033 (US\$ Million)

Table 33 AstraZeneca: Overview

Table 34 AstraZeneca: Product Portfolio

Table 35 AstraZeneca: Key Developments

Table 36 Pfizer Inc.: Overview

Table 37 Pfizer Inc.: Product Portfolio

Table 38 Pfizer Inc.: Key Developments

Table 39 Moderna, Inc.: Overview

Table 40 Moderna, Inc.: Product Portfolio

Table 41 Moderna, Inc.: Key Developments

Table 42 BioNTech SE.: Overview

Table 43 BioNTech SE.: Product Portfolio
Table 44 BioNTech SE.: Key Developments
Table 45 Arcturus Therapeutics, Inc.: Overview
Table 46 Arcturus Therapeutics, Inc.: Product Portfolio
Table 47 Arcturus Therapeutics, Inc.: Key Developments
Table 48 CureVac SE: Overview
Table 49 CureVac SE: Product Portfolio
Table 50 CureVac SE: Key Developments
Table 51 Sanofi: Overview
Table 52 Sanofi: Product Portfolio
Table 53 Sanofi: Key Developments
Table 54 etherna: Overview
Table 55 etherna: Product Portfolio
Table 56 etherna: Key Developments



## List Of Figures

### LIST OF FIGURES

Figure 1 Global mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 2 Global mRNA Vaccines and Therapeutics Market Share, By Product Type, 2024 & 2033 (%)

Figure 3 Global mRNA Vaccines and Therapeutics Market Share, By Application, 2024 & 2033 (%)

Figure 4 Global mRNA Vaccines and Therapeutics Market Share, By End-user, 2024 & 2033 (%)

Figure 5 Global mRNA Vaccines and Therapeutics Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global mRNA Vaccines and Therapeutics Market Y-o-Y Growth, By Product Type, 2023-2033 (%)

Figure 7 Prophylactic Vaccines mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 8 Therapeutic Vaccines mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 9 Therapeutic Drugs mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 10 Global mRNA Vaccines and Therapeutics Market Y-o-Y Growth, By Application, 2023-2033 (%)

Figure 11 Cancer Application in Global mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 12 Infectious Diseases Application in Global mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 13 Rare Genetic Diseases Application in Global mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 14 Others Application in Global mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 15 Global mRNA Vaccines and Therapeutics Market Y-o-Y Growth, By End-user, 2023-2033 (%)

Figure 16 Hospitals & Clinics End-user in Global mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 17 Research Organization End-user in Global mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 18 Academic Institutes End-user in Global mRNA Vaccines and Therapeutics

Market Value, 2022-2033 (US\$ Million)

Figure 19 Others End-user in Global mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 20 Global mRNA Vaccines and Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 21 North America mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 22 North America mRNA Vaccines and Therapeutics Market Share, By Product Type, 2024 & 2033 (%)

Figure 23 North America mRNA Vaccines and Therapeutics Market Share, By Application, 2024 & 2033 (%)

Figure 24 North America mRNA Vaccines and Therapeutics Market Share, By End-user, 2024 & 2033 (%)

Figure 25 North America mRNA Vaccines and Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 26 South America mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 27 South America mRNA Vaccines and Therapeutics Market Share, By Product Type, 2024 & 2033 (%)

Figure 28 South America mRNA Vaccines and Therapeutics Market Share, By Application, 2024 & 2033 (%)

Figure 29 South America mRNA Vaccines and Therapeutics Market Share, By End-user, 2024 & 2033 (%)

Figure 30 South America mRNA Vaccines and Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 31 Europe mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 32 Europe mRNA Vaccines and Therapeutics Market Share, By Product Type, 2024 & 2033 (%)

Figure 33 Europe mRNA Vaccines and Therapeutics Market Share, By Application, 2024 & 2033 (%)

Figure 34 Europe mRNA Vaccines and Therapeutics Market Share, By End-user, 2024 & 2033 (%)

Figure 35 Europe mRNA Vaccines and Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 36 Asia-Pacific mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 37 Asia-Pacific mRNA Vaccines and Therapeutics Market Share, By Product Type, 2024 & 2033 (%)

Figure 38 Asia-Pacific mRNA Vaccines and Therapeutics Market Share, By Application, 2024 & 2033 (%)

Figure 39 Asia-Pacific mRNA Vaccines and Therapeutics Market Share, By End-user, 2024 & 2033 (%)

Figure 40 Asia-Pacific mRNA Vaccines and Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 41 Middle East and Africa mRNA Vaccines and Therapeutics Market Value, 2022-2033 (US\$ Million)

Figure 42 Middle East and Africa mRNA Vaccines and Therapeutics Market Share, By Product Type, 2024 & 2033 (%)

Figure 43 Middle East and Africa mRNA Vaccines and Therapeutics Market Share, By Application, 2024 & 2033 (%)

Figure 44 Middle East and Africa mRNA Vaccines and Therapeutics Market Share, By End-user, 2024 & 2033 (%)

Figure 45 AstraZeneca: Financials

Figure 46 Pfizer Inc.: Financials

Figure 47 Moderna, Inc.: Financials

Figure 48 BioNTech SE.: Financials

Figure 49 Arcturus Therapeutics, Inc.: Financials

Figure 50 CureVac SE: Financials

Figure 51 Sanofi: Financials

Figure 52 etherna: Financials

## I would like to order

Product name: Global MRNA Vaccines and Therapeutics Market - 2025-2033

Product link: <https://marketpublishers.com/r/G421DCD4B839EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G421DCD4B839EN.html>